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Introduction. Influenza is a matter of serious concern for clini-
cians, in both outpatient and in-hospital settings. Worldwide, the 
2017-18 epidemic proved to be the most severe since 2003-04. 
We report a real-world experience regarding the management of 
patients with influenza admitted to a large teaching hospital in 
the Friuli Venezia Giulia region during the 2017-2018 influenza 
season. We also provide a practical guide for the management of 
hospitalized influenza patients. 
Methods. A retrospective observational analysis was conducted 
among all influenza patients requiring admission to our center 
during the 2017-18 season.
Results. Overall, 29 patients were admitted to the University 
Hospital of Udine during the 2017-18 season with a diagnosis 
of influenza.  B virus was responsible for the majority of cases. 
More than 65.5% of the subjects presented with a complication. 
We estimated that 41.4% of the patients admitted were affected by 
a “severe form”. All these cases required admission to the Inten-
sive Care Unit, with 27.6% and 10.3% needing Orotracheal Intu-
bation and Extracorporeal Membrane Oxygenation, respectively. 
The fatality rate was 24.1%. Notably, only 9 subjects in our cohort 
had been vaccinated. Based on the experience acquired during 
the past season, we propose a practical guide to the management 
of influenza cases in everyday hospital practice. 
Conclusion. The cornerstones of the management of all hospi-
talized influenza patients are the rapid identification and treat-
ment of severe forms. Timely and strict adherence to contact 
and respiratory precautions are also fundamental to reducing 
the risk of intra-hospital outbreaks. Despite improvements in 
antiviral therapies and supportive measures, influenza-related 
morbidity and mortality remain high. In our opinion, a univer-
sal vaccination program is the only safe and effective method 
of filling the gap.
Original article
The burden of severe cases of Influenza disease:  
the Friuli Venezia Giulia Region experience
M. BASSETTI1, M. PEGHIN1, T. GALLO2, C. PIPAN3, P. D’AGARO4, A. SARTOR3, T. BOVE5, R. COCCONI6,  
E. GRAZIANO1, N. CASTALDO1
1 Infectious Diseases Division, Department of Medicine University of Udine and Azienda Sanitaria Universitaria Integrata di Udine, 
Italy; 2 Department of Prevention, Local Health Unit 4 Medio Friuli, Udine, Italy; 3 Microbiology Unit, Department of Medicine 
University of Udine and Azienda Sanitaria Universitaria Integrata di Udine, Italy ; 4 Department of Medical, Surgical and Health 
Sciences, University of Trieste, Italy; 5 Anesthesiology and Intensive Care Medicine, Department of Medicine University of Udine 
and Azienda Sanitaria Universitaria Integrata di Udine, Italy; 6 SOC Direzione Medica di Presidio, Azienda Sanitaria Universitaria 
Integrata di Udine, Italy
Keywords
Influenza • Vaccination • Neuraminidase • Pneumonia • Respiratory illness
Summary
https://doi.org/10.15167/2421-4248/jpmh2019.60.3.1314
 OPEN ACCESS 
Introduction
Influenza is still a matter of serious concern for clini-
cians, in both outpatient and in-hospital settings. Indeed, 
worldwide, the 2017-18 epidemic proved to be the most 
severe since 2003-04. 
The “influenza season” is generally defined as the period 
of the year during which more than 80% of influenza 
cases occur. The usual length of the influenza season 
is of 8-12 weeks, from late autumn to early spring [1]. 
However this time-frame is arbitrary, as the definition 
varies widely across surveillance studies. Some authors, 
for example, regard the “influenza season” as the period 
when more than 10% of sentinel specimens prove posi-
tive for influenza virus; conversely, other experts con-
sider the “influenza season” to be the interval between 
the diagnosis of the first case, or the week in which the 
vaccination campaign begins, and the week after the di-
agnosis of the last Influenza case [2]. 
The World Health Organization (WHO) estimates that 
influenza affects almost 10-20% of the world’s popula-
tion every year and causes between 250,000 and 500,000 
deaths and 3-5 million hospitalizations [3, 4]. In Europe, 
it is estimated that approximately 10 to 30% of the pop-
ulation become infected with seasonal influenza every 
year, with several hospitalizations [5]. 
Epidemiological data on influenza circulation and influ-
enza-related illness are provided by Flunet, an online da-
tabase of the WHO Global Influenza Surveillance Net-
work, which releases weekly reports of influenza virus 
circulation and influenza-related illness. Data are pro-
vided by the National Influenza Centers of the Global 
Influenza Surveillance and Response System (GISRS), 
local laboratories, and WHO regional databases [6]. 
Since 1999, in Italy a nationwide sentinel system (In-
fluNet) coordinated by the Ministry of Health regularly 
provides national and regional surveillance data on the 
influenza season. InfluNet depends on a group of senti-
nel practitioners and pediatricians, who cover up to 2% 
of the general population. Their reports are also upload-
ed to the European Centre for Disease Prevention and 
Control (ECDC) database [7].
According to the intensity thresholds currently approved 
by the CDC to classify influenza seasonal severity, the 
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2017-18 season in Europe was the first to be classified 
as a “highly severe” across all age-groups since 2003-
2004 [1]. 
Compared with recent seasons, the 2017-2018 epidem-
ic was characterized by a higher level of circulation of 
the B virus. Indeed, B viruses were responsible for the 
majority of severe cases in 2017–2018, most of which 
occurred in patients aged over 39 years. Moreover, in 
people aged 65 years and older, an excess in all-causes 
mortality was reported by the majority of sentinel coun-
tries.
Comparable characteristics were also observed for the 
2017-2018 influenza season in Italy. According to the 
Italian surveillance system, since the beginning of the 
surveillance, in September 2017, 764 patients with lab-
oratory-confirmed influenza were admitted to intensive 
care units (ICUs). Of these, 173 died [9].
The clinical pattern of seasonal influenza infection is 
extremely heterogeneous, ranging from mild disease to 
lethal forms. 
The acute clinical presentation is similar to that of other 
influenza-like illnesses (ILI), consisting of abrupt on-
set of fever, sore throat, headache, cough and myalgia. 
The majority of cases resolve spontaneously within 
1-2 weeks, without complications. Nevertheless, some 
patients undergo a more serious clinical course, which 
may be complicated by respiratory and extra-respiratory 
disorders [10]. Among these patients, elderly people, 
younger children, pregnant women and patients with un-
derlying chronic diseases are at high risk of developing 
severe forms and influenza-related complications, such 
as bacterial pneumonia and extra-pulmonary influenza-
related disease [1]. 
Patients admitted to ICUs and those hospitalized because 
of influenza are defined as “severe cases”. It has been 
estimated that their risk of death due to influenza and in-
fluenza-related respiratory complications is 3.6-4.8-fold 
higher than that of the remaining population infected 
with seasonal influenza [11, 12].
Despite the availability of antiviral drugs for both thera-
peutic and prophylactic purposes, the only effective 
method of preventing influenza and influenza-related 
complications is vaccination [13]. 
Currently, two main types of influenza vaccines are 
available. Trivalent vaccines protect against three flu 
viruses: influenza A (H1N1) virus, influenza A (H3N2) 
virus and influenza B virus. Quadrivalent vaccines pro-
tect against the same viruses as the trivalent ones, plus 
an additional B virus. 
Different formulations of influenza vaccines exist: in-
activated, live attenuated and recombinant vaccines. 
Inactivated influenza vaccines (IIV) are egg-based com-
pounds, which may contain the whole inactivated virus, 
split virion or subunits, and induce specific antibodies 
against the hemoagglutinin (HA) component. IIVs are 
licensed for use in adults and children. IIVs also exist 
as adjuvated vaccines (with the inclusion oil-in-water 
emulsions, such as MF59) and as high-dose vaccines, 
which have been licensed for use in the elderly. A type 
of cell-based IIV has been licensed in the United States 
(US) and in some European countries [14]. A live at-
tenuated influenza vaccine (LAIV) is available in the US 
and Canada for use in adults and children, and in Europe 
for use in children and adolescents. LAIV contains four 
influenza strains (H1N1, H3N2 and the two prevalent 
B strains) and is administered intranasally. The attenu-
ated influenza virus replicates in the upper respiratory 
airways and stimulates the production of specific anti-
bodies in serum as well as in the respiratory mucosa. The 
effectiveness of LAIV against influenza A(H3N2) and 
Influenza B viruses is similar to that of IIVs. Neverthe-
less, LAIV is poorly active against influenza A(H1N1)
pdm09 viruses [15]. A Recombinant Vaccine (RV) has 
also been developed. This is made up of a purified HA 
subunit and is expressed in insect cells through bacu-
lovirus vectors. The RV is currently licensed for adults 
and destined for use in subjects who cannot receive other 
formulations. One major advantage of this vaccine is the 
short manufacturing process. It could therefore be useful 
during a pandemic season [16, 17]. 
Twice a year, the WHO organizes consultations of ex-
perts to formulate recommendations concerning the 
composition of the influenza vaccines for the following 
influenza season [18].
With regard to the 2017-18 influenza season, the triva-
lent vaccine included an A/Michigan/45/2015 (H1N1) 
pdm09-like virus, an A/Hong Kong/4801/2014 (H3N2)-
like virus, and a B/Brisbane/60/2008-like (B/Victoria 
lineage) virus. The quadrivalent vaccine also included 
a B/Phuket/3073/2013-like (B/Yamagata lineage) vi-
rus [19]. 
Overall, the effectiveness of influenza immunization 
is estimated to be around 40-60%. Effectiveness var-
ies considerably according to the circulating seasonal 
viruses, being good against A(H1N1)pdm09, moderate 
against influenza B virus, and poor against influenza 
A(H3N2) [20]. 
The WHO states that influenza vaccines should be di-
rected to protecting the whole population, with particu-
lar attention to individuals most at risk for severe forms 
of influenza and influenza-related complications. These 
“priority groups” were originally designed by the WHO 
Strategic Advisory Group of Experts on immuniza-
tion (SAGE) in 2012, and include the elderly, children, 
people with chronic conditions, pregnant women, and 
healthcare workers. In Italy, these recommendations are 
reported in the National Immunization Plan and con-
firmed every year in the influenza vaccination program 
by the Ministry of Health. According to the international 
recommendations, in Italy the minimum objective of in-
fluenza vaccine coverage in patients considered at risk is 
75%, while the optimal coverage target is 95% [21, 22]. 
In this context, our study aimed to provide real-world 
data on patients with severe influenza admitted to a large 
teaching hospital in the Friuli Venezia Giulia region dur-
ing the 2017-2018 influenza season. Based on our expe-
rience, we propose a practical guide for the management 
of hospitalized patients with influenza. 
INFLUENZA BURDEN, MANAGEMENT AND IMMUNIZATION STRATEGY
E165
Methods
Study population
We evaluated all patients admitted to the University 
Hospital of Udine (UHU) from October 1, 2017, to April 
1, 2018. Individuals diagnosed with Influenza were en-
rolled in this retrospective analysis. UHU is part of the 
Azienda Sanitaria Universitaria Integrata di Udine, and 
is located in the Friuli Venezia Giulia region, in north-
eastern Italy. UHU has 1,000 beds and serves a popula-
tion of almost 250,000 inhabitants.
Data sources
Information on the patients admitted to UHU was col-
lected from the hospital discharge records and the Re-
gional surveillance data forms provided by the Depart-
ment of Prevention of Udine [23].
Data collection and definitions
The following information was collected: the patient’s 
demographic characteristics (date of birth, gender, place 
of residence), clinical history (anamnesis of comorbidi-
ties, previous hospital admissions), history of previous 
vaccinations. The presence of at least one comorbidity 
was used to classify patients as “comorbid”. 
Influenza-like illness (ILI) and severe acute respira-
tory infections (SARI) were diagnosed according to the 
“WHO surveillance case definitions for ILI and SA-
RI” [24].
The diagnosis of influenza was based on the detection 
of influenza viral RNA by means of molecular essays 
performed on either nasopharyngeal swabs or bron-
choalveolar lavage fluid. Disease severity was defined 
according to the “WHO Guidelines for Pharmacological 
Management of Pandemic Influenza A(H1N1) 2009 and 
Other Influenza Viruses” [25].
Influenza related-complications were diagnosed accord-
ing to the ICD-10-CM diagnostic codes. 
Influenza season was defined according to the time-
frame proposed by Smetana et al. [1].
See Table I for a complete list of definitions.
Statistical analysis
Data were analyzed by means of the software package 
SPSS Statistics v.20.0 (SPSS Inc., Chicago, IL). Base-
line characteristics of the population enrolled were de-
scribed through descriptive statistics. Quantitative vari-
ables were presented as median and range, and categori-
cal variables as absolute numbers.
Results
Overall, during the 2017-18 season, 29 patients admitted 
to UHU received a diagnosis of Influenza. The charac-
teristics of the study population are summarized in Ta-
ble II. The median age of the patients admitted was 48 
years (range 0-87 years); there was an equal distribution 
of genders (51.7% men, 48.3% women). Two women 
were pregnant: one in the first trimester and one in the 
second. 
In 65.5% of cases, a B virus was isolated, in 24.1% an 
A/unsubtypized virus, in 6.9% an A H1N1 and in 3.4% 
another A virus subtype.
The seasonal peak was reached in the first two months 
of 2018, with 68.9% of all severe cases notified between 
January and February.
It was estimated that an antiviral treatment was admin-
istered (a neuroaminidase inhibitor, Oseltamivir) in 58% 
of cases. The median duration of antiviral therapy was 
7 days.
Overall, 65.5% of the subjects developed a complica-
tion (see Tab. I for details of the definition of “complica-
tion”). The majority of these had respiratory syndromes: 
44.8% complicated with bacterial pneumonia, 17.2% de-
veloped a severe acute respiratory infection (SARI) and 
27.6% an acute respiratory distress syndrome (ARDS); 
6.8 % developed myocarditis. A case of encephalitis was 
also observed in a patient with Influenza B/Yamagata 
strain isolated from a nasopharyngeal swab.
The cases classified as “severe” accounted for 41.4% of 
those admitted to UHU (see Tab. I for details of the defi-
nition of “severe case”). The median age of this popula-
tion was 59.5 years (range 0-84), and the gender distribu-
tion was almost equal (46.5% were males). The majority 
of patients (70%) had at least one comorbidity, with a 
predominance of cardiovascular diseases (48.3%). See 
Tab. II for details of “comorbidity” definition. 
All patients with severe forms were admitted to the ICU. 
Of this group, 27.6% required Orotracheal Intubation 
(OTI) and 10.3% needed to be placed on Extracorporeal 
Membrane Oxygenation (ECMO). 
Seven patients (24.1%) died; 4 had Influenza B virus iso-
lated from respiratory samples. Overall, 3 deaths were 
recorded in subjects younger than 50 years old. Of these, 
one presented with an influenza-related myocarditis and 
developed cardiogenic shock; in the other two cases, the 
final diagnosis was multi-organ failure. None of the 3 
patients aged under 50 years had been vaccinated.
Overall, 70% of the fatal cases developed pneumonia, 
ARDS was diagnosed in 4 cases, acute heart failure in 2 
cases, and myocarditis in 1 case.
Regarding vaccination coverage, only 9 (31%) of the 
UHU cohort had been vaccinated. Six vaccinated sub-
jects were older than 65 years old, 5 of whom were 
males. All the vaccinated patients were pluricomorbid 
and two of them suffered from a type of immunodefi-
ciency. Information on the type of influenza vaccine is 
not available.
Details of the clinical presentation and vaccination sta-
tus of patients admitted to UHU are summarized in Ta-
ble III. 
On the basis of the experience acquired during the 2017-
18 season, we elaborated a checklist with the aim of fa-
cilitating early diagnosis and implementing a meticulous 
clinical approach, starting from admission.
We suggest that every patient presenting with symptoms 
compatible with respiratory or systemic illness (e.g. 
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cough, fever, coryza, arthromyalgia during the Influenza 
season should undergo the following work-up:
• For patients without any risk factor for severe Influ-
enza forms: no routine testing nor routine antiviral 
treatment, unless no spontaneous improvement in 1 
week.
• For patients with one or more risk factors for severe 
Influenza forms:
- Naropharyngeal swabs for the detection of major 
respiratory viruses (e.g. Influenza, Respiratory 
Syncytial Virus, Metapneumovirus, Rhinovirus, 
Coronavirus) and major interstitial bacterial pneu-
monia (Legionella, Chlamydia and Mycoplasma).
- Legionella and Pneumococcal urinary antigens.
- Nasal and cutaneous swabs to check for Methicil-
lin-Resitant Staphylococcus aureus colonization.
- Sputum collection for gram stain and culture.
- Blood cultures. 
- Chest X-ray.
- Computerized tomography (CT) thoracic scan 
and bronchoscopy should be offered to every pa-
tient with imaging abnormalities and no results 
from the previous tests, and to every critically ill 
patient.
Regarding treatment:
• In order to provide an adequate diagnosis, no antibi-
otic or antiviral should be started before preliminary 
sample collection, unless the patient presents serious 
instability.
• Support care must be provided for every patient (ox-
ygen administration, non-invasive or invasive venti-
lation, vasopressors, intravenous fluids, etc.).
• Antivirals should be promptly administered to: criti-
cally ill people, patients affected by or at high risk 
of severe influenza forms, immunocompromised 
people, elderly and in-hospital patients. The antiviral 
should be started within 48 hours of symptom onset. 
We suggest using a neuraminidase inhibitor, such as 
Oseltamivir, Zanamivir, and Peramivir.
Empiric antibiotic treatment should be considered in 
cases of suspected superinfection and in cases at risk of 
complications with secondary infections. An adequate 
treatment for community-acquired pneumonia should be 
Tab. I. Terms and definitions.
Term Definitions
Influenza season
The period of the year during which more than 80% of influenza cases occur. The usual time-frame 
of the influenza season is of 8-12 weeks, from late autumn to early spring 
ILI
An acute respiratory infection with: measured body temperature of ≥ 38C°+ cough; with onset 
within the last 10 days
SARI
An acute respiratory infection with: history of fever or measured body temperature of ≥ 38C° + 
cough; with onset within the last 10 days, and requiring hospitalization
Severe flu
Influenza presenting as SARI, requiring ICU admission and/or ECMO 
Influenza presenting with ARDS, requiring ICU admission and/or ECMO
Influenza initially presenting as non-severe disease, and subsequently developing any of the signs 
and symptoms of progressive disease: shortness of breath, tachypnea, cyanosis, bloody or colored 
sputum, chest pain, hypotension, central nervous system complications (altered mental state, 
confusion, unconsciousness, drowsiness, seizures, weakness, or paralysis), evidence of sustained 
virus replication or invasive secondary bacterial infection 
Influenza-related 
complications
Acute respiratory failure, pneumonia, ARDS, febrile seizure, encephalitis/encephalopathy, renal 
failure, multi-organ failure, septic shock, rhabdomyolysis, myocarditis, exacerbation of underlying 
chronic disease, including asthma, COPD, chronic hepatic or renal insufficiency, diabetes, 
cardiovascular conditions
ILI: influenza like illness; SARI: severe acute respiratory infections; ARDS: Acute respiratory distress syndrome; COPD: Chronic obstructive pulmonary 
disease
Tab. II. The demographic characteristics, seasonal distribution and 
outcome of patients admitted to Udine Hospital for Influenza and 
Influenza-related complications during the 2017-18 season.
Study population
Total (n, %) 29 (100)
Age (median and range, years) 48.3 (0-87)
Male gender (n, %) 15 (51.7)
Female gender (n, %) 14 (48.3)
Pregnancy (n, %) 2 (6.9)
Subjects who had received seasonal Influenza 
vaccination (n, %)
9 (31)
Comorbidities (n, %)
• Cancer 
• Diabetes mellitus
• Cardiovascular disease
• Immunocompromised*
• Chronic respiratory conditions
• Chronic kidney disease 
• Metabolic conditions°
• Obesity
18 (62) 
2 (6.9)
4 (13.8) 
14 (48.3)
4 (16)
5 (17.2)
7 (24.1)
1 (3.4)
4 (13.7)
Seasonal distribution (n, %)
• November 
• December 
• January 
• February 
• March 
1 (3)
2 (7) 
10 (35)
10 (35)
3 (10)
Virological distribution (n, %)
• A non-subtyped virus 
• A H1N1 virus 
• A, other subtype 
• B virus 
7 (24.1)
2 (6.9) 
1 (3.4)
19 (65.5)
* Immunocompromised cases included: 1 patient affected by Common 
Variable Immunodeficiency (CVID), 1 allogeneic hematopoietic stem cell 
transplant recipient, and 2 solid organ transplant recipients; ° metabolic 
conditions included: obesity, malnutrition, chronic liver disease (including 
cirrhosis and alcoholic liver disease), alcoholism, dyslipidemia, and glucose 
intolerance
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selected. Oral antibiotics are the preferred choice; par-
enteral treatment should be selected in the case of severe 
pneumonia. The duration of the treatment should be de-
cided according to clinical evolution. Generally, standard 
antibiotic duration for community-acquired pneumonia 
is adequate. Antibiotic escalation should be considered 
in the case of insufficient improvement within 72 hours.
An algorithm to guide the management of Influenza cas-
es is reported in Figure 1.
Discussion
The 2017-18 epidemic was the most severe in all age-
groups since 2003-04. Globally, lethality rates reached 
22.6%, a disproportionate burden even in comparison 
with the 2014-15 season, when the “Fluad case” deter-
mined the lowest vaccination coverage in recent sea-
sons [26, 27].
During the 2017-18 season, in Italy a total of 764 cases 
were classified as severe. For the first time since 2009-
Fig. 1. Algorithm to guide the management of influenza cases.
Tab. III. Clinical presentation of patients admitted to Udine Hospital 
for Influenza and Influenza-related complications during the 2017-
18 season.
Clinical presentation
Admitted (n, %) 29 (100)
Admitted to ICU (n, %) 12 (41.4)
Admitted to Infectious Disease Department (n, %) 4 (13.8)
Admitted to other departments (n, %) 13 (44.8)
Requiring OTI (n, %) 8 (27.6)
Requiring ECMO (n, %) 3 (10.3%)
Receiving antiviral therapy (n, %) 17 (58.6)
Treatment duration (median days) 6.7
Severe cases (n, %) 12 (41.4)
Complications (n, %)
• Pneumoniae
• SARI
• ARDS
19 (65.5)
13 (44.8)
5 (17.2)
8 (27.6)
Outcome
• Deaths
• Cured
7 (24. 1%)
22 (75.9%)
ICU: intensive Care Unit, OTI: Orotracheal Intubation; ECMO: Extracorporeal 
Membrane Oxygenation; SARI: Severe Acute Respiratory Infection; ARDS: 
Acute respiratory distress syndrome
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10, during the past season every Italian region (except 
Molise) reported one or more severe cases of Influenza. 
The majority of cases were reported in the north of the 
country, with highest incidence in the Lombardy and 
Emilia Romagna regions [28].
Among patients with severe forms, there was a slight 
predominance of males over females (58% national data 
vs 51% in our population). The median age of these pa-
tients was 60 years, and almost 84% presented at least 
one pre-existing risk factor for developing a severe ill-
ness (diabetes, cancer, cardiovascular diseases, chronic 
respiratory diseases, immunosuppression). Fifteen se-
vere cases involved pregnant women. Only 13 of the pa-
tients affected by a severe form presented no predispos-
ing condition [9, 27]. 
Influenza-attributed deaths in Italy were 173, accounting 
for 22.6% of severe forms (versus 24.1% of our cohort); 
90% of the deaths occurred in adults, 2 of whom were 
pregnant women. All (100%) patients with severe dis-
ease needed to be admitted to the ICU, 8.5 % required 
ECMO and 41% needed OTI [9].
In our cohort, too, the majority of severe forms were re-
corded in adults, and all required admission to the ICU. 
The rate of comorbidity among UHU patients who de-
veloped a severe form was slightly lower than that re-
ported in the rest of Italy (70%). 
Nearly half of the patients with severe disease, both in 
our cohort and in the national and global surveillance 
data, were affected by a cardiovascular disease. This 
finding highlights the relationship between influenza 
infection and poor outcomes due to underlying cardio-
vascular disease. In particular, a strong association with 
increased rates of hospitalization for cardiovascular 
events and a higher risk of acute ischemic events have 
been reported [29, 30].
Concerning the time-distribution, the 2017-18 season 
started early in Italy. A and B viruses co-circulated in the 
first few weeks; subsequently, after week 48, influenza 
B largely dominated over other subtypes, being respon-
sible for 66% of cases (97% involved the B/Yamagata 
subtype) [31].
The cumulative rate of hospitalization due to influenza 
during the 2017-18 epidemic was the highest docu-
mented since 2005-2006 in all age-groups. Overall, in 
the 2017-18 season, a total of 30,453 influenza-related 
hospitalizations were reported. The majority of the hos-
pitalized patients were ≥ 65 years old [27].
Although B viruses are traditionally known to cause 
less severe disease than A subtypes, during the 2017-18 
season the predominant circulation of B/Yamagata virus 
(60% of the total viruses) in Italy was responsible for 
severe disease in most age-classes [9].
It has been estimated that 52% (308) of the severe cas-
es reported in Italy were attributable to influenza A/
H1N1pdm09 virus, 37% to influenza B virus, 9% to a 
non-subtyped A strain, and 2% to A/H3N2 virus. Of the 
cases requiring hospitalization, 72.3% were attributed to 
influenza A, 27% to influenza B, 0.4 % to influenza A 
and B co-infections, and 0.3% to a nontyped influenza 
virus. Of the patients who died, 84 (49%) were infected 
with virus A/H1N1pdm09, 76 (44%) with B virus, and 
13 (7%) with an unsubtyped influenza A virus [9, 27].
A similar distribution was also observed in our popula-
tion. In UHU, B virus predominated throughout the sea-
son, with nearly 60% of the fatal cases infected with B 
strains. 
The results of our analysis reflected the global and na-
tional epidemiology in the 2017-18 influenza season. In 
particular, we highlighted the necessity to strengthen the 
influenza surveillance system and vaccine prevention as 
a strategy for reducing the burden of influenza-related 
poor outcomes.
Our study presents several limits. First of all, we con-
ducted a purely descriptive analysis of a small sample. 
Thus, no generalization of the results can be proposed. 
Furthermore, the retrospective design of the study makes 
it impossible to rule out external factors that might have 
interfered with the outcomes and compliance. Never-
theless, it should be underlined that Italian national and 
regional data are strongly influenced by the very low 
adherence to surveillance in some areas of the country. 
Conclusions
Early recognition and prompt appropriate treatment are 
the cornerstones of the management of severe influenza 
forms. In our experience, a risk-stratified system of man-
agement is a useful strategy for the implementation of a 
cost-effective approach.
Every person who develops respiratory illness during the 
period from late autumn to early spring should be sus-
pected of having been infected with influenza. 
Patients with suspected Influenza and no risk of compli-
cated infection should be candidates for outpatient man-
agement. The illness can be expected to resolve in 7-10 
days. During recovery, the patient should be advised to 
stay at home and to avoid contact with vulnerable sub-
jects. In selected cases (e.g. people at risk of developing 
complications due to Influenza), an antiviral should be 
prescribed. If no improvement is seen within 7 days, we 
strongly recommend that the microbiological diagnosis 
be confirmed through nasopharyngeal swabbing. More-
over, the virological confirmation of influenza cases 
contributes to epidemiological monitoring and enables 
the patient’s contacts to be traced.
High-risk subjects and those with serious respiratory or 
systemic symptoms should be hospitalized and managed 
according to the best practice. We believe that currently 
approved pneumonia risk scores (e.g CURB-65, PSI) 
should be used for initial evaluation. However, an indi-
vidualized approach is mandatory.
In cases in which high severity criteria are met, the pa-
tient should be hospitalized in a medical or an intensive 
ward, according to the level of clinical complexity and 
general condition.
As a general rule, any patient who meets the following 
criteria should be considered for ICU admission: 
• Primary viral pneumonia or high CURB-65 score (4 
or 5).
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• Persistent hypoxia (PaO2 <8 Kpa) despite maximal 
oxygen support.
• Worsening hypercapnia.
• Severe acidosis (pH < 7.26).
• Septic shock.
A key point in the management of hospitalized Influ-
enza cases (whether proven or suspected) is the need for 
strict adherence to contact and respiratory precautions. 
A well-trained team plays a fundamental role in avoid-
ing in-hospital outbreaks. The recommendations are 
summarized in Table IV.
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